# CBP Updates Pharmaceutical Duty Guidance

U.S. Customs and Border Protection issued updated Section 232 guidance on September 28, 2026, explaining how importers, customs brokers, and filers must report pharmaceutical articles and ingredients under HTSUS headings 9903.04.60–9903.04.70, including applicable duty rates and exemptions. Duties took effect July 31 for companies listed in Annex III to Proclamation 11020 and began applying to other companies on September 29. Government buyers and contractors should account for the duties in affected product entries and federal-contract cost estimates, and review classification, origin, and exemption records before filing customs entries.

- Importers and brokers should use the updated guidance to determine the appropriate reporting, duty treatment, and any applicable exemption for covered pharmaceutical articles and ingredients.
- Contractors sourcing affected products should reassess landed costs and supply-chain assumptions in federal bids and contract performance estimates; the later effective date for other companies has now passed.
- Procurement teams should confirm that product classification, country-of-origin, and qualification records support the duty treatment claimed on entries.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Regulatory Compliance
**Published:** September 29, 2026

### Government Entities
- U.S. Customs and Border Protection (CBP)
- U.S. Department of Commerce (DOC)

### Sources
- [CBP Releases Updated Section 232 Guidance for Pharmaceutical Articles and Ingredients | Husch Blackwell LLP - JDSupra](https://www.jdsupra.com/legalnews/cbp-releases-updated-section-232-2944011) - JDSupra